<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189340">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628589</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-301</org_study_id>
    <secondary_id>7 December 2007</secondary_id>
    <nct_id>NCT00628589</nct_id>
  </id_info>
  <brief_title>Staccato® Loxapine Treatment of Schizophrenic Patients With Agitation</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation
      in schizophrenic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study of 2
      dose levels of Staccato Loxapine, 5 and 10 mg. Patients may receive up to 3 doses of study
      drug in a 24-hour period, depending on their clinical status. The primary endpoint is the
      change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component
      (also known as PEC) score, performed at 2 hours after the first dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PANSS Excited Component (PEC) score from baseline following Dose #1 of Staccato Loxapine, compared with placebo</measure>
    <time_frame>2 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I) score following Dose #1 of Staccato Loxapine, compared with placebo</measure>
    <time_frame>2 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events, compared with placebo</measure>
    <time_frame>24 hr</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Schizophrenic Patients With Acute Agitation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loxapine</intervention_name>
    <description>Staccato Loxapine, 5 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loxapine</intervention_name>
    <description>Staccato Loxapine, 10 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Staccato Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adult patients with schizophrenia and acute agitation

        Exclusion Criteria:

          -  Agitation caused primarily by acute intoxication

          -  History of drug or alcohol dependence

          -  Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Fishman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>June 10, 2008</lastchanged_date>
  <firstreceived_date>February 25, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Robert S. Fishman, MD, FCCP; Vice President, Medical Affairs</name_title>
    <organization>Alexza Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>schizophrenia, agitation, acute, treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
